Phase I trial using toxicity severity weights for dose finding of gemcitabine combined with radiation therapy and subsequent surgery for patients with extremity and trunk soft tissue sarcomas

An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma

“…Gemcitabine is currently tested as first-line treatment in metastatic disease alone [24,25] or in combination with adriamycin, vinorelbine, dacarbacin and docetaxel [26][27][28][29] as well as in phase I trial as a radiosensitizer in the neoadjuvant setting in conjunction to radiation therapy [30].…”